Direkt zum Inhalt
Merck

Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.

Acta cardiologica (2014-05-03)
Daisy Puttevils, Philip De Vusser, Piet Geusens, Jo Dens
ZUSAMMENFASSUNG

Patients with established rheumatoid arthritis (RA) have a higher cardiovascular morbidity and mortality in comparison with the general population. It is considered to be an independent risk factor for cardiovascular disease. The purpose of this article is to describe the mechanisms responsible for accelerated atherogenesis in RA patients and to give an overview of the effects of different RA therapies (methotrexate, TNF antagonists and other biologicals).

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
L-Amethopterin Hydrat, ≥98% (HPLC), powder
Sigma-Aldrich
L-Amethopterin Hydrat, powder, BioReagent, suitable for cell culture, ≥98% (HPLC)
Sigma-Aldrich
Methotrexat, meets USP testing specifications
SAFC
Methotrexat
Supelco
Methotrexat, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Methotrexat -Lösung, 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®
Methotrexat, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L-Amethopterin Hydrat, ≥99.0% (sum of enantiomers, HPLC)
Methotrexat für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Methotrexat für die Systemeignung, European Pharmacopoeia (EP) Reference Standard